InMode Ltd. (INMD) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $15.04. The rating moved from Overbought to Neutral on August 10, 2026.

• Public ratingNeutral (as of August 19, 2026)
• Last close$15.04
• Last changeMoved from Overbought to Neutral on August 10, 2026
• SectorHealthcare
• IndustryMedical Devices

AI analysis

InMode Ltd. sits in a niche of minimally invasive aesthetic devices with differentiated RF technology and a history of attractive margin characteristics driven by equipment plus consumables. Near-term performance will be driven by elective procedure demand and macro sensitivity; catalysts include new product adoption and international expansion while competition, regulatory outcomes, and procedure-volume cyclicality remain the principal constraints. Given muted market breadth and selective interest in growth names, expect limited near-term upside absent a clear operational or top-line inflection.

Key factors

• Market position in minimally invasive aesthetic devices with differentiated RF-based technologies and a global distributor network
• Revenue exposure to elective aesthetic procedure volumes, which track consumer confidence and macro/consumer discretionary trends
• Historically strong gross margins on capital equipment and recurring revenue from consumables and service, supporting cash generation when procedure demand is stable
• Product pipeline and geographic expansion could drive medium-term upside if procedure volumes normalize and adoption continues
• Current market environment shows muted risk appetite and selective interest in growth names, which may constrain short-term upside

Risks

• Elective-procedure cyclicality: macro weakness or reduced discretionary spending can quickly depress device placements and consumable sales
• Intensifying competition from larger medical device players and new entrants offering alternative energy-based or injectable solutions
• Regulatory and device-specific safety/recall risk that could interrupt sales and add compliance costs
• Execution risk on international expansion and distributor management; slower adoption outside core markets would limit growth
• Liquidity and balance-sheet considerations if revenue weakens materially and capex/working-capital needs persist
• Limited available social sentiment and filing updates in the provided window increases information asymmetry

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.